Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 1/2014

01-01-2014 | Original Paper

CXCR4 pathway associated with family history of melanoma

Authors: Wen-Qing Li, Jiali Han, Hans R. Widlund, Mick Correll, Yaoyu E. Wang, John Quackenbush, Martin C. Mihm, Alvaro Laga Canales, Shaowei Wu, Todd Golub, Yujin Hoshida, David J. Hunter, George Murphy, Thomas S. Kupper, Abrar A. Qureshi

Published in: Cancer Causes & Control | Issue 1/2014

Login to get access

Abstract

Purpose

Genetic predisposition plays a major role in the etiology of melanoma, but known genetic markers only account for a limited fraction of family-history-associated melanoma cases. Expression microarrays have offered the opportunity to identify further genomic profiles correlated with family history of melanoma. We aimed to distinguish mRNA expression signatures between melanoma cases with and without a family history of melanoma.

Methods

Based on the Nurses’ Health Study, family history was defined as having one or more first-degree family members diagnosed with melanoma. Melanoma diagnosis was confirmed by reviewing pathology reports, and tumor blocks were collected by mail from across the USA. Genomic interrogation was accomplished through evaluating expression profiling of formalin-fixed paraffin-embedded tissues from 78 primary cutaneous invasive melanoma cases, on either a 6K or whole-genome (24K) Illumina gene chip. Gene set enrichment analysis was performed for each batch to determine the differentially enriched pathways and key contributing genes.

Results

The CXC chemokine receptor 4 (CXCR4) pathway was consistently up-regulated within cases of familial melanoma in both platforms. Leading edge analysis showed four genes from the CXCR4 pathway, including MAPK1, PLCG1, CRK, and PTK2, were among the core members that contributed to the enrichment of this pathway. There was no association between the enrichment of CXCR4 pathway and NRAS, BRAF mutation, or Breslow thickness of the primary melanoma cases.

Conclusions

We found that the CXCR4 pathway might constitute a novel susceptibility pathway associated with family history of melanoma in first-degree relatives.
Appendix
Available only for authorised users
Literature
1.
2.
Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J et al (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367:1694–1703PubMedCentralPubMedCrossRef
3.
Hacker E, Hayward NK, Dumenil T, James MR, Whiteman DC (2012) The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian population. J Invest Dermatol 130:241–248CrossRef
4.
Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS et al (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707–714PubMedCentralPubMedCrossRef
5.
6.
Qureshi AA, Zhang M, Han J (2011) Heterogeneity in host risk factors for incident melanoma and non-melanoma skin cancer in a cohort of US women. J Epidemiol 21:197–203PubMedCrossRef
7.
Goldstein AM, Tucker MA (2013) Dysplastic nevi and melanoma. Cancer Epidemiol Biomarkers Prev 22:528–532PubMedCrossRef
8.
Yang XR, Liang X, Pfeiffer RM, Wheeler W, Maeder D, Burdette L et al (2010) Associations of 9p21 variants with cutaneous malignant melanoma, nevi, and pigmentation phenotypes in melanoma-prone families with and without CDKN2A mutations. Fam Cancer 9:625–633PubMedCentralPubMedCrossRef
9.
Goldstein AM (2004) Familial melanoma, pancreatic cancer and germline CDKN2A mutations. Hum Mutat 23:630PubMedCrossRef
10.
Duffy DL, Zhao ZZ, Sturm RA, Hayward NK, Martin NG, Montgomery GW (2010) Multiple pigmentation gene polymorphisms account for a substantial proportion of risk of cutaneous malignant melanoma. J Invest Dermatol 130:520–528PubMedCentralPubMedCrossRef
11.
Landi MT, Bauer J, Pfeiffer RM, Elder DE, Hulley B, Minghetti P et al (2006) MC1R germline variants confer risk for BRAF-mutant melanoma. Science 313:521–522PubMedCrossRef
12.
Nan H, Kraft P, Hunter DJ, Han J (2009) Genetic variants in pigmentation genes, pigmentary phenotypes, and risk of skin cancer in Caucasians. Int J Cancer 125:909–917PubMedCentralPubMedCrossRef
13.
Fan JB, Yeakley JM, Bibikova M, Chudin E, Wickham E, Chen J et al (2004) A versatile assay for high-throughput gene expression profiling on universal array matrices. Genome Res 14:878–885PubMedCrossRef
14.
Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A et al (2008) Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359:1995–2004PubMedCentralPubMedCrossRef
15.
April C, Klotzle B, Royce T, Wickham-Garcia E, Boyaniwsky T, Izzo J et al (2009) Whole-genome gene expression profiling of formalin-fixed, paraffin-embedded tissue samples. PLoS One 4:e8162PubMedCentralPubMedCrossRef
16.
Spittle C, Ward MR, Nathanson KL, Gimotty PA, Rappaport E, Brose MS et al (2007) Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. J Mol Diagn 9:464–471PubMedCentralPubMedCrossRef
17.
Sivertsson A, Platz A, Hansson J, Lundeberg J (2002) Pyrosequencing as an alternative to single-strand conformation polymorphism analysis for detection of N-ras mutations in human melanoma metastases. Clin Chem 48:2164–2170PubMed
18.
Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U et al (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4:249–264PubMedCrossRef
19.
Smyth GK (2005) Limma: linear models for microarray data. In: Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W (eds) Bioinformatics and computational biology solutions using R and Bioconductor. Springer, New York, pp 397–420CrossRef
20.
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102:15545–15550PubMedCrossRef
21.
Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J et al (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34:267–273PubMedCrossRef
22.
Teicher BA, Fricker SP (2010) CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 16:2927–2931PubMedCrossRef
23.
Wu B, Chien EY, Mol CD, Fenalti G, Liu W, Katritch V et al (2010) Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330:1066–1071PubMedCentralPubMedCrossRef
24.
Wong D, Korz W (2008) Translating an antagonist of chemokine receptor CXCR4: from bench to bedside. Clin Cancer Res 14:7975–7980PubMedCrossRef
25.
Ramos EA, Grochoski M, Braun-Prado K, Seniski GG, Cavalli IJ, Ribeiro EM et al (2011) Epigenetic changes of CXCR4 and its ligand CXCL12 as prognostic factors for sporadic breast cancer. PLoS One 6:e29461PubMedCentralPubMedCrossRef
26.
Righi E, Kashiwagi S, Yuan J, Santosuosso M, Leblanc P, Ingraham R et al (2011) CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res 71:5522–5534PubMedCrossRef
27.
Scala S, Giuliano P, Ascierto PA, Ieranò C, Franco R, Napolitano M et al (2006) Human melanoma metastases express functional CXCR4. Clin Cancer Res 12:2427–2433PubMedCrossRef
28.
29.
Kim M, Koh YJ, Kim KE, Koh BI, Nam DH, Alitalo K et al (2010) CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche. Cancer Res 70:10411–10421PubMedCrossRef
30.
Longo-Imedio MI, Longo N, Trevino I, Lazaro P, Sanchez-Mateos P (2005) Clinical significance of CXCR3 and CXCR4 expression in primary melanoma. Int J Cancer 117:861–865PubMedCrossRef
31.
Scala S, Ottaiano A, Ascierto PA, Cavalli M, Simeone E, Giuliano P et al (2005) Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 11:1835–1841PubMedCrossRef
32.
Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH et al (2000) FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2:249–256PubMedCrossRef
33.
McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, Frame MC (2005) The role of focal-adhesion kinase in cancer—a new therapeutic opportunity. Nat Rev Cancer 5:505–515PubMedCrossRef
34.
Siesser PM, Hanks SK (2006) The signaling and biological implications of FAK overexpression in cancer. Clin Cancer Res 12:3233–3237PubMedCrossRef
35.
Anderson D, Koch CA, Grey L, Ellis C, Moran MF, Pawson T (1990) Binding of SH2 domains of phospholipase C gamma 1, GAP, and Src to activated growth factor receptors. Science 250:979–982PubMedCrossRef
36.
Delgado-Martin C, Escribano C, Pablos JL, Riol-Blanco L, Rodriguez-Fernandez JL (2011) Chemokine CXCL12 uses CXCR4 and a signaling core formed by bifunctional Akt, extracellular signal-regulated kinase (ERK)1/2, and mammalian target of rapamycin complex 1 (mTORC1) proteins to control chemotaxis and survival simultaneously in mature dendritic cells. J Biol Chem 286:37222–37236PubMedCrossRef
37.
Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, Cooke CP et al (2011) Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res 17:229–235PubMedCentralPubMedCrossRef
38.
Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ et al (2009) Finding the missing heritability of complex diseases. Nature 461:747–753PubMedCentralPubMedCrossRef
39.
Pedroso I (2010) Gaining a pathway insight into genetic association data. Methods Mol Biol 628:373–382PubMedCrossRef
Metadata
Title
CXCR4 pathway associated with family history of melanoma
Authors
Wen-Qing Li
Jiali Han
Hans R. Widlund
Mick Correll
Yaoyu E. Wang
John Quackenbush
Martin C. Mihm
Alvaro Laga Canales
Shaowei Wu
Todd Golub
Yujin Hoshida
David J. Hunter
George Murphy
Thomas S. Kupper
Abrar A. Qureshi
Publication date
01-01-2014
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 1/2014
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-013-0315-9

Other articles of this Issue 1/2014

Cancer Causes & Control 1/2014 Go to the issue

Original paper

Using a composite index of socioeconomic status to investigate health disparities while protecting the confidentiality of cancer registry data

Original paper

Do longer formula feeding and later introduction of solids increase risk for pediatric acute lymphoblastic leukemia?

Original Paper

Alcohol consumption and risk of melanoma and non-melanoma skin cancer in the Women’s Health Initiative

Erratum

Erratum to: The association of active smoking with multiple cancers: national census-cancer registry cohorts with quantitative bias analysis

Original paper

Cancer mortality and quantitative oil production in the Amazon region of Ecuador, 1990–2010

Original paper

Tobacco smoking, NBS1 polymorphisms, and survival in lung and upper aerodigestive tract cancers with semi-Bayes adjustment for hazard ratio variation
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits